Kiora Pharmaceuticals, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual Form 10-K rather than a standalone fourth-quarter filing. Kiora is a clinical-stage specialty pharmaceutical company focused on ophthalmic diseases and operates as one research-and-development segment.
Business Context
- KIO-301: Lead photoswitch product candidate for vision restoration in degenerative retinal diseases, initially retinitis pigmentosa (RP). The Phase 1b ABACUS study dosed its final patient in September 2023; topline results indicated safety and tolerability at all tested doses and reported improvements across several exploratory vision and quality-of-life measures.
- KIO-104: Intravitreal DHODH inhibitor for posterior non-infectious uveitis. Management plans a Phase 2b trial beginning in the fourth quarter of 2024, subject to development and regulatory progress.
- KIO-101 and KIO-201: Development work was halted in August 2023 for these anterior-segment assets, and the Company is seeking partners for their continued development and potential commercialization.
- The Company had 12 full-time employees as of December 31, 2023 and has no approved commercial products.
Financial Results and Key Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | No significant revenue reported | No significant revenue reported | Not clearly quantified |
| General and administrative expense | $4.7 million | $8.3 million | Down $3.6 million |
| Research and development expense | $4.0 million | $3.4 million | Up $0.6 million |
| In-process R&D impairment | $1.9 million | — | Up $1.9 million |
| Change in fair value of contingent consideration | $2.0 million expense | $0.6 million expense | Up $1.4 million |
| Total operating expenses | $12.6 million | $12.3 million | Up $0.3 million |
| Operating loss | $12.6 million | $12.3 million | Loss increased $0.3 million |
| Net loss | $12.5 million | $13.6 million | Loss narrowed $1.1 million |
| Net loss attributable to common shareholders | $13.0 million | $13.6 million | Loss narrowed $0.5 million |
| Net loss per common share | $2.69 | $18.55 | Improved primarily due to higher share count |
| Net cash used in operating activities | $9.6 million | $10.4 million | Cash use decreased $0.9 million |
- Cash and cash equivalents were $2.5 million at December 31, 2023, compared with $6.0 million at December 31, 2022. Including restricted cash, year-end cash was approximately $2.5 million.
- Total assets were $13.7 million and total liabilities were $7.6 million. Stockholders’ equity was $6.1 million.
- Contingent consideration liabilities totaled approximately $5.1 million at year-end, up from $3.6 million, reflecting higher estimated probabilities of milestone achievement and related valuation changes.
- The filing does not identify material interest-bearing debt; it states that there was no interest-bearing debt in the valuation discussion. Lease liabilities totaled approximately $0.1 million.
- In-process research and development and other intangible assets totaled $8.8 million, including $8.7 million of in-process R&D. These assets represented approximately 64% of total assets.
- The Company had federal and state net operating loss carryforwards of approximately $90.2 million and $63.6 million, respectively, subject to potential utilization limitations.
Material Changes Versus 2022
- General and administrative expense declined primarily because of lower professional fees and the absence of approximately $1.0 million of executive severance incurred in 2022.
- R&D expense increased as KIO-301 clinical activity and personnel costs increased, partly offset by reduced KIO-101 and KIO-201 preclinical and manufacturing costs.
- The Company recorded a $1.9 million impairment charge after changing its strategy for KIO-101 and KIO-201 and pursuing partnerships for those programs.
- Other income, net, improved by approximately $1.6 million, primarily because 2022 included a $1.4 million warrant-liability fair-value expense.
- Financing activities generated $6.0 million in 2023, including $5.6 million from a public offering, $0.4 million from equity-line purchases, and $0.3 million from warrant exercises, partly offset by a $0.5 million contingent-consideration payment.
- Shares outstanding increased substantially during 2023 through public offerings, preferred-stock conversions, warrant exercises and other equity issuances. Potential dilution was significant: outstanding warrants totaled 13.1 million and employee options totaled 0.8 million at year-end.
- Management reported that all material weaknesses identified at December 31, 2022 were remediated by December 31, 2023. The independent auditor was not required to provide an internal-control attestation because Kiora is a smaller reporting company and non-accelerated filer.
Strategic Transactions, Outlook and Unusual Items
- On January 25, 2024, Kiora entered into a strategic development and commercialization agreement with Théa Open Innovation for KIO-301. Kiora received a $16 million upfront payment, is eligible for up to $285 million in clinical, regulatory and commercial milestones, and may receive tiered royalties up to the low-twenty-percent range. TOI is responsible for direct KIO-301 research and development costs, subject to the agreement.
- In January 2024, Kiora also completed a private placement that generated approximately $13.8 million of net proceeds. The Company reported approximately $32.4 million of gross cash receipts after year-end, including the TOI payment and financing proceeds, and expects these resources to fund planned operations into 2026.
- Management expects continuing operating losses and does not expect product candidates to be commercially available for several years, if at all. No immediate additional capital raise was anticipated within the next 24 months, but the filing states that additional funding may ultimately be required.
- The Company remains dependent on clinical success, regulatory approvals, partnerships and additional financing. The financial statements contain no adjustments for possible future effects if the Company cannot continue as a going concern.
- Nasdaq notified Kiora in July 2023 that its common stock did not meet the $1.00 minimum bid-price requirement. In January 2024, Nasdaq granted an additional compliance period through July 15, 2024. Kiora indicated that it may conduct a reverse stock split if necessary.
- The Company has no commercial manufacturing facilities and relies on third-party manufacturers, CROs, clinical sites and other vendors. It does not currently have committed commercial supply arrangements or redundant sources for certain KIO-104 and KIO-301 materials and services.
- In February 2024, Kiora completed a financing involving common stock, pre-funded warrants and additional warrants. Exercise of the accompanying warrants was subject to stockholder approval, and the warrants could provide up to approximately $30 million of additional gross proceeds if exercised.
Principal Risks and Contingencies
- Persistent losses, negative operating cash flow and dependence on future equity, debt, grant, licensing or collaboration funding.
- Clinical trials may fail, be delayed, require additional studies or produce results insufficient for regulatory approval.
- KIO-301 and KIO-104 remain unapproved; regulatory approval, market acceptance, pricing, reimbursement and commercialization are uncertain.
- Milestone liabilities are based on probability-weighted estimates and could increase materially if development or regulatory probabilities change.
- Intellectual-property protection may be challenged or expire before commercialization; the Company also faces potential third-party infringement claims.
- Reliance on third-party manufacturers and clinical service providers creates supply, quality, timing and regulatory risks.
- Substantial warrants, options and potential future financings could dilute existing stockholders.
- In-process R&D and other intangible assets are material relative to total assets and may require further impairment charges.
Investor Verification Checklist
- Verify the terms, accounting treatment and cash-receipt timing of the TOI agreement, including the $16 million upfront payment, milestone conditions, royalty rates and TOI cost obligations.
- Reconcile post-year-end financing proceeds, warrant exercises, share issuances and the resulting fully diluted share count.
- Assess whether the reported cash runway to 2026 remains reasonable after planned KIO-104 and KIO-301 development spending.
- Review the design, enrollment, timing and statistical objectives of the planned KIO-301 Phase 2 and KIO-104 Phase 2b programs.
- Evaluate the assumptions supporting the $8.7 million in-process R&D balance and the $5.1 million contingent consideration liability.
- Monitor Nasdaq bid-price compliance and any reverse stock split or delisting-related developments.
- Review potential dilution from 13.1 million outstanding warrants, 0.8 million options, restricted shares and future capital raises.
- Confirm whether KIO-101 and KIO-201 partnerships are secured and whether development of those assets will resume.